Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26139862 | 0.92 | HPGD (0.39) | HPGDMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19124383 | 0.82 | LMNA (0.37) | MEN1KMT2ABRD4P2RX7LMNA | |
| SCHEMBL15427281 | 0.79 | MEN1 (0.41) | MEN1KMT2ABRD4P2RX7LMNA | |
| SCHEMBL25573605 | 0.78 | — | — | |
| SCHEMBL15617682 | 0.77 | BRD4 (0.35) | BRD4P2RX7 | |
| SCHEMBL15621584 | 0.76 | LMNA (0.56) | BRD4P2RX7LMNA | |
| SCHEMBL19116500 | 0.76 | SMN1; SMN2 (0.42) | HPGDMEN1KMT2ABRD4SMN1; SMN2 | |
| SCHEMBL15427263 | 0.75 | BRD4 (0.33) | BRD4P2RX7LMNA | |
| SCHEMBL22259417 | 0.75 | ALDH1A1 (0.41) | BRD4SMN1; SMN2P2RX7 | |
| SCHEMBL19151155 | 0.75 | LMNA (0.42) | MEN1KMT2ABRD4P2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680090-B2 | Sulfonyl containing benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | HPGD 1787/4885MEN1 4770/4885CYP1A2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.